Insulin prices have increased dramatically over the past decade in the United States. This report presents results from international price comparisons of insulins using a price index approach. The average gross manufacturer price for a standard unit of insulin in 2018 was more than ten times the price in a sample of 32 foreign countries:$98.70 in the U.S., compared with $8.81 in the 32 non-U.S. OECD countries for which we have prescription drug data. The U.S. prices for the mix of insulin used in the U.S. were 8.1 times prices paid in all non-U.S. OECD countries combined.
- 2020 Drug Pricing Report to Congress (PDF)
- 2019 Drug Pricing Report to Congress (PDF)
- 2016 Drug Pricing Report to Congress (PDF)
- Comparison of U.S. and Prices for Top Medicare Part B Drugs by Total Expenditures (PDF)
- Savings Available Under Full Generic Substitution of Multiple Source Brand Drugs in Medicare Part D (PDF)
This content is in the process of Section 508 review. If you need immediate assistance accessing this content, please submit a request to Kenneth Finegold, (202) 557-9553, Kenneth.Finegold@hhs.gov. Content will be updated pending the outcome of the Section 508 review.